Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.
Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.
复制标题
DOI：
10.1016/j.cllc.2011.03.025
复制
发表时间：
2011-07
影响因子：
3.6
通讯作者：
He B
中科院分区：
文献类型：
--
作者：
Okamoto J;Kratz JR;Hirata T;Mikami I;Raz D;Segal M;Chen Z;Zhou HM;Pham P;Li H;Yagui-Beltran A;Ray MR;Koizumi K;Shimizu K;Jablons D;He B
I 期非小细胞肺癌 (NSCLC) 的 5 年生存率为 50% 至 70%，这表明我们目前的分期方法不能充分预测结果。空气孔同源盒 2 (EMX2) 是一种含有同源结构域的转录因子，可调节已知促进肺部肿瘤发生的关键发育途径。本研究评估了 EMX2 作为肺腺癌（包括细支气管肺泡癌 (BAC)）预后生物标志物的重要性。对 144 名接受手术切除的肺腺癌患者进行了研究。分别使用定量实时逆转录酶聚合酶链反应和免疫组织化学分析EMX2 mRNA和蛋白表达。使用 Kaplan-Meier 方法和多变量 Cox 比例风险回归模型评估 EMX2 mRNA 表达水平与临床结果的关联。与相匹配的邻近正常组织相比，肺腺癌中 EMX2 mRNA 表达显着下调 (P < .001)。同样发现 EMX2 蛋白表达在肺腺癌中下调。 EMX2 高 mRNA 表达组的总生存 (OS) 显着优于 EMX2 低 mRNA 表达组 (P = .005)。亚组分析还表明 I 期患者 (P = .01) 和 BAC 患者 (P = .03) 的生存率有所改善。最后，在腺癌患者中，EMX2 高 mRNA 表达组的无复发生存 (RFS) 显着优于 EMX2 低 mRNA 表达组 (P < .001)。 EMX2 表达在肺腺癌中下调。低 EMX2 mRNA 表达与肺腺癌患者（尤其是 I 期疾病和 BAC）患者的 OS 和 RFS 降低显着相关。
The 5-year survival rate for stage I non–small-cell lung cancer (NSCLC) of 50% to 70% indicates that our current staging methods do not adequately predict outcome. Empty spiracles homeobox 2 (EMX2) is a homeo–domain-containing transcription factor that regulates a key developmental pathway known to promote lung tumorigenesis. This study assessed the significance of EMX2 as a prognostic biomarker in lung adenocarcinoma including bronchioloalveolar carcinoma (BAC). 144 patients with lung adenocarcinoma undergoing surgical resection were studied. Quantitative real-time reverse transcriptase polymerase chain reaction and Immunohistochemistry were used to analyze EMX2 mRNA and protein expression, respectively. Association of EMX2 mRNA expression levels with clinical outcomes was evaluated using the Kaplan-Meier method and a multivariate Cox proportional hazards regression model. EMX2 mRNA expression was significantly downregulated in lung adenocarcinoma compared with matched adjacent normal tissue (P < .001). EMX2 protein expression was similarly found to be downregulated in lung adenocarcinoma. The EMX2-high mRNA expressing group had statistically significant better overall survival (OS) than the EMX2-low mRNA expressing group (P = .005). Subgroup analysis also demonstrated improved survival in stage I patients (P = .01) and patients with BAC (P = .03). Lastly, the EMX2-high mRNA expressing group had statistically significant better recurrence-free survival (RFS) than the EMX2-low mRNA expression group in patients with adenocarcinoma (P < .001). EMX2 expression is downregulated in lung adenocarcinoma. Low EMX2 mRNA expression is significantly associated with decreased OS and RFS in patients with lung adenocarcinoma, particularly with stage I disease and BAC.
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
4.6
作者：
Ligon, KL;Echelard, Y;Rowitch, DH
通讯作者：
Rowitch, DH
影响因子：
9.6
作者：
Detterbeck, Frank C.;Boffa, Daniel J.;Tanoue, Lynn T.
通讯作者：
Tanoue, Lynn T.
EMX2在表观遗传上沉默并抑制人类肺癌的生长。
影响因子：
8
作者：
Okamoto, J.;Hirata, T.;Chen, Z.;Zhou, H-M;Mikami, I.;Li, H.;Beltran, A.;Johansson, M.;Coussens, L. M.;Clement, G.;Shi, Y.;Zhang, F.;Koizumi, K.;Shimizu, K.;Jablons, D.;He, B.
通讯作者：
He, B.
影响因子：
82.9
作者：
Beer, DG;Kardia, SLR;Hanash, S
通讯作者：
Hanash, S